Full-Time

Vice President Non-Interventional Research

Iterative Health

Iterative Health

51-200 employees

AI-powered polyp detection for colorectal cancer

No salary listed

Boston, MA, USA + 2 more

More locations: Southlake, TX, USA | New York, NY, USA

Hybrid

Two days on-site per week required.

Bachelor's, Master's, MBA, PharmD, PhD, JD, MD

Category
Biology & Biotech (1)

Get referred to Iterative Health

See people who can refer or advise you

Requirements
  • BS/BA or higher degree required; advanced degree (MBA, MPH, or equivalent) strongly preferred.
  • 10+ years of experience in general management, operations leadership, or a highly strategic and operational role, including but not limited to direct P&L or business unit ownership.
  • Demonstrated track record of building and scaling a business or business unit from the ground up — including standing up new capabilities, managing vendors, and driving commercial pipelines.
  • Proven people leadership experience with a track record of building, developing, and scaling teams through periods of growth.
  • Exceptional organizational and project management skills with the ability to manage multiple high-stakes workstreams simultaneously.
  • Strong executive presence and communication skills — able to represent the business credibly with sponsors, vendors, and senior internal stakeholders.
  • Comfortable operating with significant autonomy and building structure in ambiguous, fast-moving environments.
Responsibilities
  • Own full P&L accountability for the non-interventional research business, including revenue, cost, and margin performance.
  • Own the go-to-market strategy for Iterative Health's non-interventional research business — defining the service offering, target customer segments, competitive positioning, and path to scale.
  • Work with Life Sciences to scope the collections service model, establish pricing frameworks, and develop the materials and narrative needed to bring the offering to market.
  • Partner with the Life Sciences team to develop and progress a pipeline of collections studies, supporting sponsor engagement and proposal development.
  • Identify and size the resourcing, infrastructure, and capability requirements needed to support the strategy and inform investment decisions.
  • Lead the end-to-end build-out of the non-interventional research business — standing up operational capabilities and establishing the processes and infrastructure needed to execute at scale.
  • Work cross-functionally with site operations leaders and executive leadership to identify and onboard the right sites and networks network to stand up and support collections studies across different therapeutic areas and specialty networks
  • Own vendor contracting and relationships, including selection, negotiation, onboarding, and ongoing performance management for all collections-related vendors.
  • Own execution quality and sponsor satisfaction on active collections studies, serving as the senior point of escalation and ensuring trials are delivered to the highest standard.
  • Define and track KPIs across the business; use performance data to identify gaps, course-correct quickly, and communicate progress to senior leadership.
  • Lead, develop, and hold accountable a team including pre-screeners, central Clinical Research Coordinators, and a Clinical Operations Manager — setting clear performance targets and maintaining a high-performance culture.
  • Set the operational tempo for the team — running structured operations, maintaining visibility into study and team performance, and driving accountability at every level.
  • Performs related duties as requested
Desired Qualifications
  • Background in management consulting or a high-growth startup environment.
  • Experience in life sciences, clinical research, or healthcare services — particularly in biological specimen collections studies.
  • Familiarity with clinical trial operations, site network management, or sponsor engagement.
  • Experience working in a healthcare technology or multi-site research organization.

Iterative Health develops and deploys AI-powered tools for gastrointestinal (GI) care. Its main product is SKOUT®, an FDA-cleared device that helps doctors find adenomas (polyps) during GI procedures, supporting clinical judgment rather than replacing it. The company also offers AI-enabled documentation and data standardization technologies to improve the quality of patient care and to streamline clinical trials, enabling consistent reporting across institutions. By combining AI image analysis, data-driven insights, and streamlined research workflows, Iterative Health aims to improve colorectal cancer prevention and diagnosis and to extend high-quality GI care to underserved populations around the world.

Company Size

51-200

Company Stage

Series C

Total Funding

$262.2M

Headquarters

Boston, Massachusetts

Founded

2017

Get referred to Iterative Health

See people who can refer or advise you

Simplify Jobs

Simplify's Take

What believers are saying

  • July 8, 2026 GANJ partnership adds New Jersey GI research sites and IBD volume.
  • August 11, 2026 Mount Sinai advisor Samin Sharma deepens cardiology credibility for sponsors.
  • May 14, 2026 NextStage site acquisitions and April financing accelerate cardiology and obesity growth.

What critics are saying

  • Sponsor concentration risks hit quickly if cardiology or obesity trials underperform in 2026.
  • Community-network expansion increases quality-control failures; one site scandal can damage the whole brand.
  • If payment from pharma stalls, Iterative Health's capital-heavy network model becomes existentially fragile.

What makes Iterative Health unique

  • Iterative Health embeds research inside community GI practices, not standalone academic centers.
  • Its April 30, 2026 Series C backs a multispecialty network across four continents.
  • SKOUT gives colonoscopy teams real-time adenoma detection, strengthening the GI workflow.

Help us improve and share your feedback! Did you find this helpful?

Benefits

Vision/Dental/ Medical Insurance

Life/Disability Insurance

Parental Leave

Stock Options

Flexible Work Hours

Unlimited Paid Time Off

Growth & Insights and Company News

Headcount

6 month growth

-2%

1 year growth

-1%

2 year growth

-6%
Associated Press
Aug 11th, 2026
Iterative Health appoints Mount Sinai's Dr Samin K. Sharma as honorary chair of interventional cardiology

Iterative Health has appointed Dr Samin K. Sharma as scientific advisor and honorary chair of interventional cardiology. Dr Sharma is director of the Cardiovascular Clinical Institute at Mount Sinai Hospital and director of interventional cardiology at Mount Sinai Health System. Dr Sharma has over 30 years of experience and has authored more than 350 peer-reviewed articles. He pioneered the use of the Rotablator technique for complex coronary blockages. The appointment follows Iterative Health's recent US site network expansion, including acquiring cardiology research sites from NextStage Clinical Research and partnering with US Heart & Vascular. The company's network spans more than 100 sites across three continents in GI, hepatology, obesity, and cardiology research.

Business Wire
Aug 11th, 2026
Iterative Health appoints Dr. Samin K. Sharma at Mount Sinai Hospital as honorary chair of Interventional Cardiology.

Iterative Health appoints Dr. Samin K. Sharma at Mount Sinai Hospital as honorary chair of Interventional Cardiology. CAMBRIDGE, Mass.-(BUSINESS WIRE)-Iterative Health, a healthcare technology and services company powering the acceleration of clinical research, today announced the appointment of Samin K. Sharma, MD, FACC, MSCAI, Director of the Cardiovascular Clinical Institute at The Mount Sinai Hospital, as a scientific advisor and honorary chair of Interventional Cardiology. In this role, Dr. Sharma brings best-in-class clinical and scientific leadership from one of the foremost academic medical centers to advance the company's cardiology strategy. "Dr. Sharma is a world-renowned physician recognized for his clinical judgment, commitment to patient-centered care, and contributions to the field," said Jonathan Ng, founder and CEO of Iterative Health. "His experience will help strengthen our therapeutic expertise, protocol and trial design, and scientific publications, ultimately helping our sites move studies forward with the excellence and rigor sponsors expect." Dr. Sharma is director of the S.P. and Seema Lohia Cardiovascular Clinical Institute and director of interventional cardiology at Mount Sinai Health System, where he also serves as president of the Mount Sinai Heart Network. With more than 30 years of experience, he is one of the most awarded cardiologists for his contributions to medical science. He is also credited with pioneering the use of the Rotablator technique for complex, calcified coronary blockages, has authored more than 350 peer-reviewed articles, and sits on the editorial boards of several cardiology journals. Dr. Sharma is passionate about medical education, mentoring fellows and experienced cardiologists alike through innovative teaching methods, including symposiums and live-broadcast cases that reach thousands. "There's a real gap between what a trial protocol asks for and what's actually workable at the bedside, and it can cost a study valuable time," said Dr. Sharma. "Iterative Health has built a research network around closing that gap, and it's an honor to help the company strengthen its impact in advancing cardiology research." The appointment follows Iterative Health's recent US site network expansion, including the acquisition of established cardiology research sites from NextStage Clinical Research and a strategic partnership with US Heart & Vascular. The company's network spans more than 100 high-performing sites across three continents in GI, hepatology, obesity, and cardiology research. About Iterative Health Iterative Health is a healthcare technology and services company powering the acceleration of clinical research to transform patient outcomes. By combining deep expertise in clinical trials with cutting-edge AI, we empower research teams and study sponsors to expand and expedite access to novel therapeutics for patients in need. The company has headquarters in Cambridge, Massachusetts, and New York, New York. For more information, visit www.iterative.health and follow us on LinkedIn for the latest company updates. Contacts. Media Contact Iterative Health: Andrea Sampson President/CEO, Sampson Public Relations Group [email protected] More News From Iterative Health CAMBRIDGE, Mass.-( BUSINESS WIRE )-Iterative Health and Gastroenterology Associates of New Jersey partnered to expand access to GI clinical research in New Jersey... CAMBRIDGE, Mass.-( BUSINESS WIRE )-Iterative Health announced the acquisition of three cardiology sites from NextStage Clinical Research... CAMBRIDGE, Mass.-( BUSINESS WIRE )-Iterative Health announced the presentation of updated scientific research at Digestive Disease Week (DDW) 2026...

Associated Press
Jul 8th, 2026
Iterative Health partners with GANJ to expand GI clinical research across New Jersey

Iterative Health has partnered with Gastroenterology Associates of New Jersey (GANJ) to expand clinical research access across New Jersey. The collaboration establishes two research sites in Toms River and Clifton, joining Iterative Health's network of over 110 sites globally. GANJ operates 28 locations across New Jersey with more than 60 healthcare professionals. The partnership integrates clinical research into community GI care, leveraging New Jersey's population of over 9.5 million residents and its ethnic diversity. Iterative Health will serve as GANJ's research partner, combining the practice's clinical expertise with its AI-powered technology and operational model. The collaboration focuses particularly on inflammatory bowel disease, with GANJ recently establishing a Comprehensive IBD Care Centre. Additional research sites are under discussion across GANJ's broader provider network. Iterative Health operates the largest community-embedded research site network in the US for GI, hepatology, obesity, and cardiology clinical development.

Planet First Partners
Jun 30th, 2026
Iterative Health raises $77M Series C to accelerate clinical trials with AI-powered research network

Planet First Partners has invested in Iterative Health, a healthcare technology company focused on accelerating clinical research. The investment follows Iterative Health's recent $77 million Series C funding round led by Intrepid Growth Partners and Google Ventures, with participation from EDBI, a family office, Insight Partners, and Obvious Ventures. Iterative Health operates a clinical research network spanning over 100 sites across North America, Europe, India, and Australia. The company uses AI and centralised operations to improve trial efficiency, achieving twice faster site activation and three times higher patient enrolment compared to industry standards. The Series C funds will support expansion into cardiology and obesity research, building on the company's existing focus on gastroenterology and hepatology. Iterative Health partners with over 40 pharmaceutical, biotech, and CRO organisations.

Business Wire
May 14th, 2026
Iterative Health acquires 3 cardiology sites from NextStage Clinical Research in Texas

Iterative Health, a healthcare technology and services company, has acquired three cardiology research sites in Texas from NextStage Clinical Research. The sites, located in Beaumont, Port Arthur and Waco, bring experienced research teams and established cardiovascular trial operations. The acquisition expands Iterative Health's cardiology footprint as part of its strategy to embed clinical research within community care settings. The company operates over 100 sites across three continents, supported by a 250-person team and proprietary AI tools for patient recruitment and trial design. Cardiovascular disease affects nearly half of US adults, yet clinical trial access remains uneven. The addition strengthens Iterative Health's capabilities across therapeutic areas including gastroenterology, hepatology and obesity, whilst providing patients access to innovative cardiovascular therapies and devices.